Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Oct 18:12:752292.
doi: 10.3389/fphar.2021.752292. eCollection 2021.

Editorial: Cannabidiol Treatment in Neurotherapeutic Interventions

Gustavo Gonzalez-Cuevas  1 , Maria S Garcia-Gutierrez  2 , Francisco Navarrete  2 , Giordano de Guglielmo  3 , Jorge Manzanares  2
Affiliations
Editorial

Editorial: Cannabidiol Treatment in Neurotherapeutic Interventions

Gustavo Gonzalez-Cuevas et al. Front Pharmacol. .
No abstract available

Keywords: CBD-cannabidiol; cannabidiol; neuropsychiatric disorders (NPD); neurotherapeutic; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Comment on

  • Editorial on the Research Topic Cannabidiol Treatment in Neurotherapeutic Interventions

References

    1. Adams R., Hunt M., Clark J. H. (1940). Structure of Cannabidiol, a Product Isolated from the Marihuana Extract of Minnesota Wild Hemp. I. J. Am. Chem. Soc. 62, 196–200. 10.1021/ja01858a058 - DOI
    1. Bitencourt R. M., Takahashi R. N. (2018). Cannabidiol as a Therapeutic Alternative for post-traumatic Stress Disorder: from Bench Research to Confirmation in Human Trials. Front. Neurosci. 12, 502. 10.3389/fnins.2018.00502 - DOI - PMC - PubMed
    1. Britch S. C., Babalonis S., Walsh S. L. (2021). Cannabidiol: Pharmacology and Therapeutic Targets. Psychopharmacology (Berl) 238 (1), 9–28. 10.1007/s00213-020-05712-8 - DOI - PMC - PubMed
    1. Brown J. D., Winterstein A. G. (2019). Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use. J. Clin. Med. 8 (7), 989. 10.3390/jcm8070989 - DOI - PMC - PubMed
    1. Gonzalez-Cuevas G., Martin-Fardon R., Kerr T. M., Stouffer D. G., Parsons L. H., Hammell D. C., et al. (2018). Unique Treatment Potential of Cannabidiol for the Prevention of Relapse to Drug Use: Preclinical Proof of Principle. Neuropsychopharmacology 43 (10), 2036–2045. 10.1038/s41386-018-0050-8 - DOI - PMC - PubMed

Publication types